These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 27140800)

  • 1. Bioequivalence study with lapatinib powder for oral suspension and the original tablet formulation in cancer patients.
    Koch KM; Ferron-Brady G; Lemmon C; Cartee L; Hollyfield H; D'Amelio AM; Piepszak A; Swaby RF; Curran D; Arya N
    Clin Pharmacol Drug Dev; 2015; 4(3):203-9. PubMed ID: 27140800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors.
    Cox DS; Allred A; Zhou Y; Infante JR; Gordon MS; Bendell J; Jones S; Burris H; Orford K
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):287-94. PubMed ID: 27136909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors.
    Sarantopoulos J; Goel S; Chung V; Munster P; Pant S; Patel MR; Infante J; Tawbi H; Becerra C; Bruce J; Kabbinavar F; Lockhart AC; Tan E; Yang S; Carlson G; Scott JW; Sharma S
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):921-927. PubMed ID: 27681579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects.
    Frohna P; Lu J; Eppler S; Hamilton M; Wolf J; Rakhit A; Ling J; Kenkare-Mitra SR; Lum BL
    J Clin Pharmacol; 2006 Mar; 46(3):282-90. PubMed ID: 16490804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, open-label 3-way crossover study to investigate the relative bioavailability and bioequivalence of crushed sildenafil 20 mg tablets mixed with apple sauce, extemporaneously prepared suspension (EP), and intact sildenafil 20 mg tablets in healthy volunteers under fasting conditions.
    Gao X; Ndongo MN; Checchio TM; Cook J; Duncan B; LaBadie RR
    Clin Pharmacol Drug Dev; 2015 Jan; 4(1):74-80. PubMed ID: 27128005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.
    Falchook GS; Venkatakrishnan K; Sarantopoulos J; Kurzrock R; Mita AC; Fu S; Mita MM; Zhou X; Jung JA; Ullmann CD; Milch C; Rosen LS
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):563-72. PubMed ID: 26073352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours.
    Devriese LA; Koch KM; Mergui-Roelvink M; Matthys GM; Ma WW; Robidoux A; Stephenson JJ; Chu QS; Orford KW; Cartee L; Botbyl J; Arya N; Schellens JH
    Invest New Drugs; 2014 Jun; 32(3):481-8. PubMed ID: 24346280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors.
    Oostendorp RL; Loftiss J; Goel S; Smith DA; Dar MM; Witteveen PO; Cohen RB; Lewis LD; Kurian S; Patnaik A; Rosing H; Beijnen JH; Voest EE; Burris H; J
    Int J Clin Pharmacol Ther; 2009 Mar; 47(3):195-206. PubMed ID: 19281729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers.
    Cantarini MV; McFarquhar T; Smith RP; Bailey C; Marshall AL
    Clin Ther; 2004 Oct; 26(10):1630-6. PubMed ID: 15598479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials.
    Metzmann K; Schnell D; Jungnik A; Ring A; Theodor R; Hohl K; Meinicke T; Friedrich C
    Int J Clin Pharmacol Ther; 2014 Jul; 52(7):549-63. PubMed ID: 24755124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults.
    Nguyen L; Benrimoh N; Xie Y; Offman E; Lacy S
    Anticancer Drugs; 2016 Aug; 27(7):669-78. PubMed ID: 27139820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relative bioavailability of gefitinib administered by granular formulation.
    Cantarini MV; Bailey CJ; Collins B; Smith RP
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):203-8. PubMed ID: 17909808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.
    Plummer R; Swaisland H; Leunen K; van Herpen CM; Jerusalem G; De Grève J; Lolkema MP; Soetekouw P; Mau-Sørensen M; Nielsen D; Spicer J; Fielding A; So K; Bannister W; Molife LR
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):723-9. PubMed ID: 26242220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers.
    Parrillo-Campiglia S; Ercoli MC; Umpierrez O; Rodríguez P; Márquez S; Guarneri C; Estevez-Parrillo FT; Laurenz M; Estevez-Carrizo FE
    Clin Ther; 2009 Oct; 31(10):2224-32. PubMed ID: 19922893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients.
    Cassidy J; Twelves C; Cameron D; Steward W; O'Byrne K; Jodrell D; Banken L; Goggin T; Jones D; Roos B; Bush E; Weidekamm E; Reigner B
    Cancer Chemother Pharmacol; 1999; 44(6):453-60. PubMed ID: 10550565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase 1, Open-Label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 (Trifluridine/Tipiracil) Tablets Relative to an Oral Solution Containing Equivalent Amounts of Trifluridine and Tipiracil.
    Becerra CR; Yoshida K; Mizuguchi H; Patel M; Von Hoff D
    J Clin Pharmacol; 2017 Jun; 57(6):751-759. PubMed ID: 28070894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linagliptin fixed-dose combination with metformin is bioequivalent to co-administration of linagliptin and metformin as individual tablets.
    Buschke S; Ring A; Friedrich C; Metzmann K; Meinicke T
    Int J Clin Pharmacol Ther; 2014 Jul; 52(7):537-48. PubMed ID: 24755123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
    Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects.
    Wang MN; Kuang Y; Gong LY; Hua Y; Pei Q; Guo CX; Cao Y; Huang J; Yang GP
    Invest New Drugs; 2020 Dec; 38(6):1826-1835. PubMed ID: 32535812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.